Swiss company Abionic has scored CHF20m ($21m) to bankroll a multinational study into the efficacy of its Pancreatic Stone Protein (PSP) test, a rapid, point-of-care diagnostic for sepsis and septic shock. Abionic believes the five-minute PSP test could be used in emergency and intensive care departments to help physicians assess a patent's risk of sepsis and decide when to start antibiotic treatment.
The Series C round was led by a cluster of high-net-worth individuals including Peter Brabeck-Letmathe, former CEO and chairman of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?